Skip to content

Free cash flow at other companies

Medtronic logo
MedtronicMDT
$2.09B+0.8%
AdaptHealth logo
AdaptHealthAHCO
-$27.49M-47,297%
Mannkind logo
MannkindMNKD
-$7.25M-8.0%
Abbott logo
AbbottABT
$916M-1.8%
Omnicell logo
OmnicellOMCL
$42.07M+185%
Insulet logo
InsuletPODD

Other financials

Income statement

See full
Revenue$247.2M+5.5%
Gross profit$136.8M+15.5%
Operating income-$17.4M+85.6%
Net income-$20.4M+84.4%
EPS (diluted)-$0.30+84.8%

Balance sheet

See full
Cash & equivalents$179.3M+235%
Total debt$734.7M+49.0%
Total equity$132.4M-14.7%
Total assets$1.2B+25.1%

Cash flow

See full
Operating cash flow$11.1M+160%
CapEx$6.3M+111%

Valuation

See full
Market cap$1.03B-23.6%
Enterprise value$1.58B-11.3%
P/S-0.4×

Profitability

See full
Gross margin54.9%+2.7pp
Operating margin-8.2%-2.9pp
Net margin-9.2%-3.1pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-65.7%-14.7pp
Debt / equity5.5×+2.4×
Current ratio3.6×+1.3×

Where this comes from

Calculated from Tandem Diabetes Care’s reported figures.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tandem Diabetes Care's free cash flow?
Tandem Diabetes Care (TNDM) reported free cash flow of $4.79M in Q1 2026.
How has Tandem Diabetes Care's free cash flow changed year-over-year?
Tandem Diabetes Care's free cash flow increased by 122.5% year-over-year, from -$21.24M to $4.79M.
What is the long-term trend for Tandem Diabetes Care's free cash flow?
Over 2 years (2021 to 2024), Tandem Diabetes Care's free cash flow has grown at a -77.3% compound annual growth rate (CAGR), from $97.18M to $4.99M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.